Homepage
Author:
Adagene Inc.
Posted Date:
April 2, 2026
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
Adagene Inc.
April 2, 2026
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Adagene Inc.
April 2, 2026
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Adagene Inc.
April 2, 2026
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
Adagene Inc.
April 2, 2026
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
Adagene Inc.
March 17, 2026
Adagene to Participate in Two Upcoming Investor Conferences
Adagene Inc.
February 17, 2026
Adagene Provides Business Update and 2026 Objectives
Adagene Inc.
January 27, 2026
